The global oncology clinical trials market size is accounted at USD 14.27 billion in 2025 and is forecasted to hit around USD 22.76 billion by 2034, representing a CAGR of 5.28% from 2025 to 2034. The North America market size was estimated at USD 5.71billion in 2024 and is expanding at a CAGR of 5.41% during the forecast period. The market sizing and forecasts are revenue-based (USD Million/Billion), with 2024 as the base year.
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: Oncology Clinical Trials Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. Oncology Clinical Trials Market, by Phase Type
8.1.1. Phase I
8.1.1.1. Market Revenue and Forecast
8.1.2. Phase II
8.1.2.1. Market Revenue and Forecast
8.1.3. Phase III
8.1.3.1. Market Revenue and Forecast
8.1.4. Phase IV
8.1.4.1. Market Revenue and Forecast
9.1. Oncology Clinical Trials Market, by Study Design
9.1.1. Interventional Studies
9.1.1.1. Market Revenue and Forecast
9.1.2. Observational Studies
9.1.2.1. Market Revenue and Forecast
9.1.3. Expanded Access Studies
9.1.3.1. Market Revenue and Forecast
10.1. North America
10.1.1. Market Revenue and Forecast, by Phase Type
10.1.2. Market Revenue and Forecast, by Study Design
10.1.3. U.S.
10.1.3.1. Market Revenue and Forecast, by Phase Type
10.1.3.2. Market Revenue and Forecast, by Study Design
10.1.4. Rest of North America
10.1.4.1. Market Revenue and Forecast, by Phase Type
10.1.4.2. Market Revenue and Forecast, by Study Design
10.2. Europe
10.2.1. Market Revenue and Forecast, by Phase Type
10.2.2. Market Revenue and Forecast, by Study Design
10.2.3. UK
10.2.3.1. Market Revenue and Forecast, by Phase Type
10.2.3.2. Market Revenue and Forecast, by Study Design
10.2.4. Germany
10.2.4.1. Market Revenue and Forecast, by Phase Type
10.2.4.2. Market Revenue and Forecast, by Study Design
10.2.5. France
10.2.5.1. Market Revenue and Forecast, by Phase Type
10.2.5.2. Market Revenue and Forecast, by Study Design
10.2.6. Rest of Europe
10.2.6.1. Market Revenue and Forecast, by Phase Type
10.2.6.2. Market Revenue and Forecast, by Study Design
10.3. APAC
10.3.1. Market Revenue and Forecast, by Phase Type
10.3.2. Market Revenue and Forecast, by Study Design
10.3.3. India
10.3.3.1. Market Revenue and Forecast, by Phase Type
10.3.3.2. Market Revenue and Forecast, by Study Design
10.3.4. China
10.3.4.1. Market Revenue and Forecast, by Phase Type
10.3.4.2. Market Revenue and Forecast, by Study Design
10.3.5. Japan
10.3.5.1. Market Revenue and Forecast, by Phase Type
10.3.5.2. Market Revenue and Forecast, by Study Design
10.3.6. Rest of APAC
10.3.6.1. Market Revenue and Forecast, by Phase Type
10.3.6.2. Market Revenue and Forecast, by Study Design
10.4. MEA
10.4.1. Market Revenue and Forecast, by Phase Type
10.4.2. Market Revenue and Forecast, by Study Design
10.4.3. GCC
10.4.3.1. Market Revenue and Forecast, by Phase Type
10.4.3.2. Market Revenue and Forecast, by Study Design
10.4.4. North Africa
10.4.4.1. Market Revenue and Forecast, by Phase Type
10.4.4.2. Market Revenue and Forecast, by Study Design
10.4.5. South Africa
10.4.5.1. Market Revenue and Forecast, by Phase Type
10.4.5.2. Market Revenue and Forecast, by Study Design
10.4.6. Rest of MEA
10.4.6.1. Market Revenue and Forecast, by Phase Type
10.4.6.2. Market Revenue and Forecast, by Study Design
10.5. Latin America
10.5.1. Market Revenue and Forecast, by Phase Type
10.5.2. Market Revenue and Forecast, by Study Design
10.5.3. Brazil
10.5.3.1. Market Revenue and Forecast, by Phase Type
10.5.3.2. Market Revenue and Forecast, by Study Design
10.5.4. Rest of LATAM
10.5.4.1. Market Revenue and Forecast, by Phase Type
10.5.4.2. Market Revenue and Forecast, by Study Design
11.1. Novartis
11.1.1. Company Overview
11.1.2. Product Offerings
11.1.3. Financial Performance
11.1.4. Recent Initiatives
11.2. Merck & Co.
11.2.1. Company Overview
11.2.2. Product Offerings
11.2.3. Financial Performance
11.2.4. Recent Initiatives
11.3. Pfizer Inc.
11.3.1. Company Overview
11.3.2. Product Offerings
11.3.3. Financial Performance
11.3.4. Recent Initiatives
11.4. Roche
11.4.1. Company Overview
11.4.2. Product Offerings
11.4.3. Financial Performance
11.4.4. Recent Initiatives
11.5. Bristol Myers Squibb
11.5.1. Company Overview
11.5.2. Product Offerings
11.5.3. Financial Performance
11.5.4. Recent Initiatives
11.6. AstraZeneca
11.6.1. Company Overview
11.6.2. Product Offerings
11.6.3. Financial Performance
11.6.4. Recent Initiatives
11.7. Johnson & Johnson
11.7.1. Company Overview
11.7.2. Product Offerings
11.7.3. Financial Performance
11.7.4. Recent Initiatives
11.8. Eli Lilly and Company
11.8.1. Company Overview
11.8.2. Product Offerings
11.8.3. Financial Performance
11.8.4. Recent Initiatives
11.9. GlaxoSmithKline
11.9.1. Company Overview
11.9.2. Product Offerings
11.9.3. Financial Performance
11.9.4. Recent Initiatives
11.10. Sanofi
11.10.1. Company Overview
11.10.2. Product Offerings
11.10.3. Financial Performance
11.10.4. Recent Initiatives
12.1. Primary Research
12.2. Secondary Research
12.3. Assumptions
13.1. About Us
13.2. Glossary of Terms
For questions or customization requests, please reach out to us at sales@precedenceresearch.com
Plan your call and get expert insights!
Schedule a Meeting
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
Report Description
Get a Sample